SEMAX and SELANK: A Comparative Research Overview

Structural Origins

SEMAX is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of adrenocorticotropic hormone (ACTH 4-10), with a proline-glycine-proline extension added to enhance metabolic stability. Unlike the full ACTH molecule, SEMAX does not activate adrenal steroidogenesis — its activity is confined to the central nervous system.

SELANK is also a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), derived from the immunoregulatory tetrapeptide tuftsin, with the same PGP stability extension. Its structural core confers both immunomodulatory and neurological activity — a dual profile that distinguishes it from SEMAX.

Primary Mechanisms: Where They Diverge

SEMAX's most documented mechanism involves upregulation of neurotrophic factors, particularly BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor). Dolotov et al. (2006) demonstrated significant BDNF elevation in the hippocampus and frontal cortex following SEMAX administration in rats, with the effect persisting beyond the peptide's estimated half-life — suggesting downstream gene expression changes rather than direct receptor binding alone.

SELANK's primary documented mechanism is modulation of GABAergic neurotransmission. Zozulya et al. (2001) demonstrated that SELANK produced anxiolytic effects in rodent models comparable to the benzodiazepine phenazepam, but without respiratory suppression, motor impairment, or withdrawal syndrome — properties consistent with a GABAergic modulator that does not act directly at the benzodiazepine binding site.

Both peptides modulate monoamine neurotransmitter systems — serotonin, dopamine, and noradrenaline — but the emphasis and direction of these effects differ between compounds and across experimental models.

Cognitive and Neuroprotective Research: SEMAX

SEMAX has been most extensively studied in the context of stroke recovery and neurological rehabilitation. Gusev and Skvortsova (2000) conducted early clinical observations suggesting SEMAX may accelerate neurological recovery in ischemic stroke patients, with improvements in motor function and cognitive recovery metrics. This research supported its registration as a pharmaceutical in Russia.

At the cellular level, SEMAX has been shown to protect neurons against oxidative stress and ischemic insult in vitro and in vivo, partly through BDNF upregulation and modulation of apoptotic pathways. Its effects on optic nerve protection in glaucoma models and potential applications in neurodegenerative research have been noted in the literature.

Anxiolytic and Immunomodulatory Research: SELANK

SELANK's research profile centers on anxiety reduction and stress response modulation. Semenova et al. (2010) demonstrated that SELANK normalizes elevated anxiety states in rodent models without the sedative or amnesic effects associated with conventional anxiolytics. Its effect on enkephalin metabolism — specifically reducing the activity of enkephalin-degrading enzymes — has been proposed as a contributing mechanism.

The tuftsin component of SELANK contributes an immunomodulatory dimension not present in SEMAX. Research has documented SELANK's ability to modulate cytokine expression, including interleukin profiles, and to influence lymphocyte activity — positioning it as a compound of interest in psychoneuroimmunology research where anxiety and immune function intersect.

Administration and Pharmacokinetics

Both peptides are administered intranasally in clinical and research settings, which allows for direct entry into the CNS via olfactory pathways while bypassing first-pass hepatic metabolism. Intranasal delivery results in rapid CNS exposure within minutes of administration in animal models.

As peptides, both are subject to enzymatic degradation into their constituent amino acids, which are then cleared through standard metabolic pathways. The PGP extension in both molecules provides resistance to common peptidases, contributing to their relative stability compared to shorter peptide fragments.